coramsine, page-16

re: coramsine/spike/egr Agree with this sentiment. While the share price languishes, the value of the projects increase as they move further along the timeline. Sooner or later, a re-rating will come. The technology seems to valuable for this not to occur. It might take a month, it might take a year.

That said, 2005 should be a good year for Solbec. The release of (favorable) announcments regarding psoriasis and cancer will kick things off well and there should be some significant advances towards OD status, phase 2 trials and a partnership agreement. This will change Solbec's image from "highly speculative" to "well established". The market cap will increase as a result.